Private company

XOMA Royalty Corp

American pharmaceutical preparations company, incorporated in Nevada.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersNV
Incorporated inNV²
Business address2200 Powell Street, Suite 310, Emeryville, Ca 94608²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

110.0%Operating margin³

306.4%Net margin³

55.6%Revenue growth, 2025³

37.8%Return on equity³

1.15×Debt to equity³

Where the money goes

Where each dollar of revenue went, fiscal 2025

Profit

Research and development5¢$1.7M
Income tax0¢$103.0K
Profit95¢$31.7M

Out of $10.3M in revenue.³

Where each dollar of operating cash went, fiscal 2025

Dividends paidShare buybacks

Dividends paid25¢$5.5M
Share buybacks75¢$16.0M

Out of $2.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.³

Financial statements

Revenue⁴⁵⁶⁷⁸³$10.3M in 2025−40% since 2019

Operating income⁴⁵⁶⁷⁸³$11.4M in 2025

Net income⁴⁵⁶⁷⁸³$31.7M in 2025

Fiscal year	2019	2020	2021	2022	2023	2024	2025
Revenue	$17.3M⁴	$27.9M⁵	$36.5M⁶	$4.2M⁷	$2.6M⁸	$6.7M³	$10.3M³
Research and development	$1.3M⁴	$170.0K⁵	$171.0K⁶	$153.0K⁷	$143.0K⁸	$2.9M³	$1.7M³
Selling, general and admin
Operating income	-$3.9M⁴	$12.4M⁵	$17.5M⁶	-$17.4M⁷	-$41.8M⁸	-$40.0M³	$11.4M³
Interest
Income tax	$0⁴	-$1.5M⁵	$91.0K⁶	-$15.0K⁷	$0⁸	-$5.7M³	$103.0K³
Net income	-$2.0M⁴	$13.3M⁵	$15.8M⁶	-$17.1M⁷	-$40.8M⁸	-$13.8M³	$31.7M³
Earnings per share	-$0.23⁴	$0.82⁵	$0.69⁶	-$1.98⁷	-$4.04⁸	-$1.65³	$1.53³
Earnings per share (diluted)	-$0.23⁴	$0.78⁵	$0.65⁶	-$1.98⁷	-$4.04⁸	-$1.65³	$1.46³

Total assets⁴⁵⁶⁷⁸³$272.7M in 2025+185% since 2019

Total liabilities⁴⁵⁶⁷⁸³$168.7M in 2025+226% since 2019

Shareholders’ equity⁵⁶⁷⁸³$83.9M in 2025+91% since 2019

Cash⁵⁶⁷⁸³$82.9M in 2025+46% since 2019

Long-term debt⁴⁵⁷⁸³$96.5M in 2025+256% since 2019

Fiscal year	2019	2020	2021	2022	2023	2024	2025
Cash	$56.7M⁵	$86.4M⁶	$93.3M⁶	$57.8M⁷	$153.3M⁸	$101.7M³	$82.9M³
Current assets	$60.0M⁴	$88.1M⁵	$97.0M⁶	$61.3M⁷	$169.3M⁸	$125.6M³	$117.3M³
Total assets	$95.7M⁴	$125.3M⁵	$166.6M⁶	$140.4M⁷	$234.3M⁸	$221.3M³	$272.7M³
Current liabilities	$8.9M⁴	$12.3M⁵	$13.0M⁶	$6.8M⁷	$19.5M⁸	$24.4M³	$34.8M³
Long-term debt	$27.1M⁴	$12.8M⁵		$0⁷	$118.5M⁸	$106.9M³	$96.5M³
Total liabilities	$51.7M⁴	$38.9M⁵	$24.7M⁶	$16.4M⁷	$145.6M⁸	$139.4M³	$168.7M³
Shareholders’ equity	$44.0M⁵	$86.4M⁶	$141.9M⁷	$124.0M⁸	$88.7M⁸	$61.9M³	$83.9M³
Shares outstanding	9.8M shares⁴	11.2M shares⁵	11.3M shares⁶	11.5M shares⁷	11.5M shares⁸	12.0M shares³	11.9M shares³

Cash from operations⁴⁵⁶⁷⁸³$2.9M in 2025

Capital spending⁵⁸³$20.0K in 2024+122% since 2020

Free cash flow⁵⁸³-$13.8M in 2024

Dividends paid⁶⁷⁸³$5.5M in 2025+56% since 2021

Share buybacks³$16.0M in 2025+123308% since 2024

Fiscal year	2019	2020	2021	2022	2023	2024	2025
Cash from operations	-$285.0K⁴	$10.1M⁵	$22.7M⁶	-$12.9M⁷	-$18.2M⁸	-$13.7M³	$2.9M³
Capital spending		$9.0K⁵			$17.0K⁸	$20.0K³
Free cash flow		$10.1M			-$18.2M	-$13.8M
Dividends paid			$3.5M⁶	$5.5M⁷	$5.5M⁸	$5.5M³	$5.5M³
Share buybacks						$13.0K³	$16.0M³

Compare XOMA Royalty Corp with another company

Leadership

Who has led XOMA Royalty Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Chief financial officer

2010201520202025

Chief executive officerOwen Hughes Jan 5, 2023 to now¹²
Chief executive officerJames R. Neal May 22, 2017 to Jul 18, 2022¹³
Chief executive officerJohn Varian Oct 28, 2011 to Mar 22, 2016¹⁴
Chief executive officerSteven B. Engle Aug 13, 2007 to Feb 11, 2011¹⁵
Chief executive officerJohn L. Castello Jan 4, 2006 to Feb 11, 2008¹⁶
ChairOwen Hughes Sep 27, 2023 to Oct 4, 2023¹⁷
ChairSteven B. Engle Feb 11, 2008 to Feb 11, 2011¹⁸
PresidentSteven B. Engle Aug 13, 2007 to Feb 11, 2011¹⁵
PresidentJohn L. Castello Jan 4, 2006 to Feb 11, 2008¹⁶
Chief financial officerJeffrey Trigilio Jan 14, 2026 to now¹⁹
Chief financial officerThomas M. Burns Apr 7, 2015 to Jan 14, 2026²⁰
Chief financial officerFred Kurland Mar 2, 2009 to Apr 7, 2015²¹
Chief financial officerJ. David Boyle Ii. Mar 1, 2006 to May 14, 2008²²

Board members and other officers (34)

Chief Investment OfficerBradley Sitko Jan 5, 2023 to now²³
Chief Business OfficerDeepshikha Datta Feb 26, 2018 to Feb 15, 2019²⁴
VP Business DevelopmentJames R. Neal Mar 3, 2014 to Nov 3, 2016²⁵
VP Clinical Dev. & CMOPaul D. Rubin Jun 2, 2011 to Mar 22, 2016²⁶
VP FinanceFred Kurland Jan 2, 2009 to Jan 2, 2009²⁷
CSMOPatrick J. Scannon Md. Phd. Jan 4, 2006 to Mar 22, 2016²⁸
Board memberOwen Hughes Jan 5, 2023 to now¹²
Board memberMark N. Lampert May 20, 2022 to May 19, 2023²⁹
Board memberMatthew D. Perry May 20, 2022 to now³⁰
Board memberHeather L. Franklin Aug 10, 2021 to now³¹
Board memberNatasha Hernday Jul 2, 2020 to now³²
Board memberBarbara Kosacz Jan 3, 2019 to now³³
Board memberJames R. Neal Mar 23, 2017 to Jul 18, 2022³⁴
Board memberKelvin Neu Jul 23, 2012 to Jul 23, 2012³⁵
Board memberL.p. 14159 Jul 23, 2012 to Jan 6, 2015³⁶
Board memberL.p. 667 Jul 23, 2012 to Jan 6, 2015³⁷
Board memberFelix Baker Oct 31, 2012 to Jan 6, 2015³⁸
Board memberJulian Baker Oct 31, 2012 to Jan 6, 2015³⁸
Board memberJoseph M. Limber Dec 13, 2012 to now³⁹
Board memberJack L. Wyszomierski Aug 26, 2010 to now⁴⁰
Board memberTimothy P. Walbert Nov 15, 2010 to May 22, 2017⁴¹
Board memberJohn Varian Dec 10, 2008 to May 22, 2017⁴²
Board memberCharles J. Fisher Jr. Aug 1, 2007 to Jan 11, 2011⁴³
Board memberSteven B. Engle Aug 13, 2007 to Nov 2, 2007¹⁵
Board memberJohn L. Castello Jan 4, 2006 to Feb 11, 2008¹⁶
Board memberPatrick J. Scannon Md. Phd. Jan 4, 2006 to Mar 22, 2016²⁸
Board memberArthur Kornberg Md. May 24, 2006 to Aug 27, 2007⁴⁴
Board memberJames G. Andress May 24, 2006 to May 14, 2008⁴⁵
Board memberNess W. Denman Van May 24, 2006 to May 20, 2022⁴⁶
Board memberPatrick J. Zenner May 24, 2006 to Jul 26, 2010⁴⁷
Board memberPeter Barton Hutt May 24, 2006 to May 22, 2017⁴⁸
Board memberWilliam K. Bowes Jr. May 24, 2006 to Jun 1, 2015⁴⁹
General counselMaricel Perea Montano Aug 14, 2025 to now⁵⁰
General counselChristopher J. Margolin Jan 4, 2006 to Feb 14, 2012⁵¹

Former names

XOMA CorpFeb 14, 2012 to Jul 9, 2024²
XOMA LTD /DE/Dec 13, 2001 to Jan 17, 2012²
XOMA CORP /DE/Apr 23, 1996 to Mar 19, 1998²

Timeline

Jan 5, 2023New chief executive Owen Hughes becomes CEO¹²
May 22, 2017New chief executive James R. Neal becomes CEO¹³
Oct 28, 2011New chief executive John Varian becomes CEO¹⁴
Aug 13, 2007New chief executive Steven B. Engle becomes CEO¹⁵
Jan 4, 2006New chief executive John L. Castello becomes CEO¹⁶

Filings

307 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 71 major events, 106 insider forms, 27 large holders, 84 other. The latest 20:

The 307 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 27 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARXOMA Royalty Corp filings on SEC EDGAR
2
SEC EDGARXOMA Royalty Corp filings on SEC EDGAR
3
SEC EDGARXOMA Royalty Corp 10-K for fiscal 2025
4
SEC EDGARXOMA Royalty Corp 10-K for fiscal 2019
5
SEC EDGARXOMA Royalty Corp 10-K for fiscal 2020
6
SEC EDGARXOMA Royalty Corp 10-K for fiscal 2021
7
SEC EDGARXOMA Royalty Corp 10-K for fiscal 2022
8
SEC EDGARXOMA Royalty Corp 10-K for fiscal 2023
9
SEC EDGARXOMA Royalty Corp 10-Q for fiscal 2025
10
SEC EDGARXOMA Royalty Corp 10-Q for fiscal 2025
11
SEC EDGARXOMA Royalty Corp 10-Q for fiscal 2026
12
SEC EDGAROwen Hughes, Chief executive officer
13
SEC EDGARJames R. Neal, Chief executive officer
14
SEC EDGARJohn Varian, Chief executive officer
15
SEC EDGARSteven B. Engle, Chief executive officer
16
SEC EDGARJohn L. Castello, Chief executive officer
17
SEC EDGAROwen Hughes, Chair
18
SEC EDGARSteven B. Engle, Chair
19
SEC EDGARJeffrey Trigilio, Chief financial officer
20
SEC EDGARThomas M. Burns, Chief financial officer
21
SEC EDGARFred Kurland, Chief financial officer
22
SEC EDGARJ. David Boyle Ii., Chief financial officer
23
SEC EDGARBradley Sitko, Chief Investment Officer
24
SEC EDGARDeepshikha Datta, Chief Business Officer
25
SEC EDGARJames R. Neal, VP Business Development
26
SEC EDGARPaul D. Rubin, VP Clinical Dev. & CMO
27
SEC EDGARFred Kurland, VP Finance
28
SEC EDGARPatrick J. Scannon Md. Phd., CSMO
29
SEC EDGARMark N. Lampert, Board member
30
SEC EDGARMatthew D. Perry, Board member
31
SEC EDGARHeather L. Franklin, Board member
32
SEC EDGARNatasha Hernday, Board member
33
SEC EDGARBarbara Kosacz, Board member
34
SEC EDGARJames R. Neal, Board member
35
SEC EDGARKelvin Neu, Board member
36
SEC EDGARL.p. 14159, Board member
37
SEC EDGARL.p. 667, Board member
38
SEC EDGARFelix Baker, Board member
39
SEC EDGARJoseph M. Limber, Board member
40
SEC EDGARJack L. Wyszomierski, Board member
41
SEC EDGARTimothy P. Walbert, Board member
42
SEC EDGARJohn Varian, Board member
43
SEC EDGARCharles J. Fisher Jr., Board member
44
SEC EDGARArthur Kornberg Md., Board member
45
SEC EDGARJames G. Andress, Board member
46
SEC EDGARNess W. Denman Van, Board member
47
SEC EDGARPatrick J. Zenner, Board member
48
SEC EDGARPeter Barton Hutt, Board member
49
SEC EDGARWilliam K. Bowes Jr., Board member
50
SEC EDGARMaricel Perea Montano, General counsel
51
SEC EDGARChristopher J. Margolin, General counsel